zanolimumab
mAbexperimental
Zanolimumab is an investigational human monoclonal antibody and an immunosuppressive drug. It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma. Development of the drug was ultimately discontinued with termination of all trials. — Wikipedia
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Sep 1, 2002 (NCT00042406)
Timeline
Indications
Mechanism of action
- Leukocyte surface antigen CD47INHIBITOR
CD47 inhibitor
CD4 other
Induces a strong depletion of CD4-positive T cells (antibody-dependent cell-mediated cytotoxicity (ADCC)).
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaZanolimumab ↗
- ChEMBLCHEMBL2109472 ↗
- ChEMBLCHEMBL2108063 ↗
Also known as
- humax-cd4
- mdx-016
- mdx-cd4
- zanolimumab
- zanolimumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01160445 | Phase 2 | Jun 1, 2010 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00877656 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2005 | Emergent BioSolutions, Genmab |
| NCT00127881 | Phase 3 | Jul 1, 2005 | Emergent BioSolutions |
| NCT00071084 | Phase 2 | May 1, 2003 | Emergent BioSolutions |
| NCT00071071 | Phase 2 | Apr 1, 2003 | Emergent BioSolutions |
| NCT00042406 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2002 | Emergent BioSolutions |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Emergent BioSolutions | For profit | 5 | 5 | 2 | 2002 |
| Genmab | For profit | 1 | 0 | 1 | 2005 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2010 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2010 |
4 organizations
Page 1 / 1